Suping Li

Suping Li is a Full Professor at the National Center for Nanoscience and Technology of China (NCNST) and at the University of the Chinese Academy of Sciences (UCAS). She received her Ph.D. degree from Beihang University in 2011. From 2015 to 2017, she worked as a visiting fellow at the Johns Hopkins School of Medicine and Massachusetts Institute of Technology (MIT), respectively. Her interests are in nanomedicines and the design of biology-inspired nanomachines to overcome the currently known barriers in tumor therapy. In recent years, she has published several papers in prestigious journals such as Nature Biotechnology, Nature Biomedical Engineering, Advanced Materials, and Nature Communications, among others, as the first/co-first or co-corresponding author. Her work has been extensively acknowledged by her international peers, and highlighted by prestigious journals (e.g., Nature Reviews Drug Delivery, Nature Reviews Cancer). One of her studies was selected as a Chinese ‘Technical Advances Top Ten’ and ‘Top Technical Advances’ in the world in 2018. Dr. Li holds seven patents (three of the Chinese patents are under consideration for clinical use) and she has been invited to present at numerous biomaterials- and biotechnology-related international conferences, such as the 14th Asian Congress in Biotechnology (ACB 2019), the 9th Asian Conference on Nanoscience & Nanotechnology (AsiaNano 2018) and SWCR 2023. She has been awarded many academic honors, including the “Ten Thousand Talent Program Young top-notch talent”, the “Beijing Municipal Natural Science Foundation for Distinguished Young Scientists” and the “CAS Interdisciplinary Innovation Team Award”.

1.Suping Li^#, Qiao Jiang^#, Shaoli Liu^#, Yinlong Zhang^#, Yanhua Tian, Chen Song, Jing Wang, Yiguo Zou, Gregory J Anderson, Jing-Yan Han, Yung Chang, Yan Liu, Chen Zhang, Liang Chen, Guangbiao Zhou, Guangjun Nie^*, Hao Yan^*, Baoquan Ding^*, Yuliang Zhao^*. A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo. Nature Biotechnology. 2018, 36(3): 258-264. (Highlighted by Nat Biotechnol, Nat Biomed Eng, Nat Rev Cancer, Sci Transl Med, Trends Mol Med, Sci China Chem)

2.Suping Li^#, Yinlong Zhang^#, Shih-Hsin Ho, Bozhao Li, Meifang Wang, Xiongwei Deng, Na Yang, Guangna Liu, Zefang Lu, Junchao Xu, Quanwei Shi, Jing-Yan Han, Lirong Zhang, Yan Wu*, Yuliang Zhao*, Guangjun Nie*. Combination of tumour-infarction therapy and chemotherapy via the co-delivery of doxorubicin and thrombin encapsulated in tumour-targeted nanoparticles. Nature Biomedical Engineering. 2020, 4(7): 732-742.

3.Suping Li^#, Yinlong Zhang^#, Jing Wang^#, Ying Zhao, Tianjiao Ji, Xiao Zhao, Yanping Ding, Xiaozheng Zhao, Ruifang Zhao, Feng Li, Xiao Yang, Shaoli Liu, Zhaofei Liu, Jianhao Lai, Andrew K. Whittaker, Gregory J. Anderson, Jingyan Wei, Guangjun Nie*. Nanoparticle-mediated local depletion of tumour-associated platelets disrupts vascular barriers and augments drug accumulation in tumours. Nature Biomedical Engineering, 2017, 1(8): 667-679. (Highlighted by Nat Biomed Eng)

4.Xin Zeng^#, Jie Sun^#, Suping Li^#, Jiyun Shi^#, Han Gao, Wei Sun Leong, Yiqi Wu, Minghui Li, Chengxin Liu, Ping Li, Jing Kong, Yi-Zhou Wu^*, Guangjun Nie^*, Yuming Fu^*, Gen Zhang^*. Blood-triggered generation of platinum nanoparticle functions as an anti-cancer agent. Nature Communications. 2020, 11(1): 567.

5.Junchao Xu, Yinlong Zhang^*, Jiaqi Xu, Guangna Liu, Chunzhi Di, Xiao Zhao, Xiang Li, Yao Li, Ningbo Pang, Chengzhi Yang, Yanyi Li, Bozhao Li, Zefang Lu, Meifang Wang, Kesheng Dai, Rong Yan, Suping Li^*, Guangjun Nie^*. Engineered Nanoplatelets for Targeted Delivery of Plasminogen Activators to Reverse Thrombus in Multiple Mouse Thrombosis Models. Advanced Materials. 2020, 32(4): e1905145.

6.Shaoli Liu^#, Yinlong Zhang^#, Xiao Zhao^#, Jing Wang, Chunzhi Di, Ying Zhao, Tianjiao Ji, Keman Cheng, Yongwei Wang, Long Chen, Yingqiu Qi, Suping Li^*, Guangjun Nie^*. Tumor-Specific Silencing of Tissue Factor Suppresses Metastasis and Prevents Cancer-Associated Hypercoagulability. Nano Letters. 2019, 19(7): 4721-4730.

7.Bozhao Li^#, Tianjiao Chu^#, Jingyan Wei^*, Yinlong Zhang, Feilong Qi, Zefang Lu, Chao Gao, Tianjiao Zhang, Ershuai Jiang, Junchao Xu, Jiaqi Xu, Suping Li^*, Guangjun Nie^*. Platelet membrane-coated nanoparticles enable vascular disrupting agent combining anti-angiogenic drug for improved tumor vessel impairment. Nano letters. 2021, 21(6):2588-2595.

8.Xiu-Ping Zhang^#, Bozhao Li^#, Zefang Lu^#, Ming-Gen Hu, Guo-Dong Zhao, Shuai Xu, Zhouliang Wu, Tianjiao Chu, Feilong Qi, Suying Wu, Guangjun Nie, Suping Li^*, Rong Liu^*. Nanoparticle-based combination of LMWH and doxorubicin for the efficient treatment of hepatocellular carcinoma with portal vein tumor thrombus. Nano Today. 2023, 49: 101787.

9.Bozhao li^#, Xiuping Zhang^#, Zhouliang Wu^#, Tianjiao Chu, Zhenlin Yang, Shuai Xu, Suying Wu, Yunkai Qie, Zefang Lu, Feilong Qi, Minggen Hu, Guodong Zhao, Jingyan Wei, Yuliang Zhao, Guangjun Nie, Huan Meng^*, Rong Liu^*, Suping Li^*. Reducing Postoperative Recurrence of Early-Stage Hepatocellular Carcinoma by a Wound-Targeted Nanodrug. Advanced Science. 2022, 9(20): e2200477.

10.Zifu Li, Chunzhi Di, Suping Li^*, Xiangliang Yang^*, Guangjun Nie^*. Smart Nanotherapeutic Targeting of Tumor Vasculature. Accounts of Chemical Research. 2019, 52(9): 2703-2712.

11.Bozhao Li, Jingyan Wei^*, Chunzhi Di, Zefang Lu, Feilong Qi, Yinlong Zhang, Wei Sun Leong, Lele Li, Guangjun Nie^*, Suping Li^*. Molecularly engineered truncated tissue factor with therapeutic aptamers for tumor targeted delivery and vascular infarction. Acta Pharmaceutica Sinica B. 2021, 11(7): 2059-2069.

12.Fei-Long Qi^#, Mei-Fang Wang^#, Bo-Zhao Li, Ze-Fang Lu, Guang-Jun Nie^*, Su-ping Li^*. Reversal of the immunosuppressive tumor microenvironment by nanoparticle-based activation of immune-associated cells. Acta Pharmacologica Sinica. 2020, 41(7): 895-901.

13.Suping Li^#, Qiao Jiang^#, Baoquan Ding^*, Guangjun Nie^*. Anticancer Activities of Tumor-killing Nanorobots. Trends in Biotechnology. 2019, 37(6): 573-577.